Bioanalytical Outsourcing Soars as Drugs Grow More Complex
Introduction The global pharma analytical testing outsourcing market is expected to reach $14.6 billion by 2030, expanding at a CAGR of 8.4%, as per ReportLinker. Bio-based drugs and biopharmaceuticals are likely to drive this growth as they require a high level of testing for validating efficacy and safety. Newer modalities, like cell and gene therapies […]
Pharma supply chains: From fragile to agile
Introduction The pharmaceutical supply chain is undergoing a major transformation, shifting from fragile to agile models to enhance resilience. The COVID-19 pandemic exposed vulnerabilities in global supply networks, highlighting the risks of over-reliance on select markets like China and India for active pharmaceutical ingredients (APIs) and raw materials. Today, pharma companies and CDMOs are adopting […]
CMOs bask in pill promise
Introduction Contract manufacturing organizations (CMOs) are witnessing increased demand for outsourcing oral solid dosage (OSD), particularly from Europe. The global OSD contract manufacturing market, valued at $34.3 billion in 2022, is projected to grow at a 6.0% CAGR until 2030. Factors driving growth in OSDs include increasing complexity of new drug molecules, R&D investments by […]
ADCs-Biological missiles for targeted therapies
Introduction The concept of targeted cytotoxic drug delivery to reduce systemic toxicity while increasing treatment efficacy was first introduced by Paul Ehrlich in 1913. However, it was only a century later that this concept turned into reality when the first antibody-drug conjugate (ADC) gained regulatory approval. ADCs continue to demonstrate efficacy across different tumor types, […]
Pharma 4.0-Taking CDMOs factory by storm
Introduction Contract manufacturing firms are ramping up the adoption of Pharma 4.0 technologies as regulators and customers increasingly look for transparency and integrity in manufacturing data. Pharma 4.0 enables a new level of transparency in manufacturing that has never been seen before. It allows access to the same data for every player along the supply […]
Net zero pledge: CDMOs go greener
Introduction According to industry reports, the pharmaceutical sector accounts for as much as 4.4% of emissions worldwide, and if no action is taken, its greenhouse gas (GHG) emissions could triple by 2050. Interestingly, compared to Scope 1 and Scope 2 emissions, Scope 3 emissions comprise most of the pharma sector’s carbon footprint. As the industry […]
New modalities hog the limelight
Introduction The biopharmaceutical industry is experiencing a paradigm shift as advanced therapies such as mRNA-based drugs, cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), and bispecific antibodies gain momentum. According to industry reports, the gene therapy market is poised to grow at a CAGR of 18.6% from 2022 to 2027. Similarly, the global bispecific antibody […]
Integrated outsourcing for drug development
Introduction This article explores the pros and cons of integrated versus standalone outsourcing services based on an industry-wide survey conducted by Pharma Intelligence in partnership with Syngene. According to the survey, the pharmaceutical industry is shifting toward integrated outsourcing for drug development to streamline processes, reduce costs, and accelerate timelines. It also reveals that nearly […]
pDNA-Cracking the Code
Introduction pDNA is critical to many advanced and emerging therapies, including cell and gene therapies and mRNA vaccines, as it is the key starting material used in these therapies. Since the quality of the pDNA is vital to the success of these programs, biologics organizations must make decisions around pDNA design early in the development […]
How to overcome solubility challenges by applying amorphous solid dispersion
Introduction Poor solubility is among the primary causes of low bioavailability for orally administered drugs. Because over 85% of pharmaceuticals are administered orally, improving solubility is a top priority among drug developers. Converting a crystalline form of a drug to an amorphous solid dispersion (ASD) form results in enhanced bioavailability and solubility for many products. […]